by: Parent Project Muscular Dystrophy
Sarepta Therapeutics, in partnership with Roche, has announced the EMBARK study of delandistrogene moxeparvovec (SRP-9001) in participants with Duchenne is now fully enrolled. Delandistrogene moxeparvovec (SRP-9001) is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.
As always, we are so grateful to all of the families who participate in clinical trials, and we look forward to continued updates from Sarepta and Roche as the trial continues.
Read the Community Bulletin:
Dear Duchenne Community,
Sarepta Therapeutics and Roche would like to thank the Duchenne community for their interest and ongoing participation in the EMBARK (SRP-9001-301) study. The EMBARK study is fully enrolled. We are thankful for the contributions of patients, families, investigators, regulatory agencies, and advocacy leaders, whose efforts made this possible.
